Bluebird Faces Another Delay with BLA for Sickle Cell Gene Therapy

In an earnings call Wednesday, bluebird bio revealed it is unlikely to meet its first-quarter goal to submit a Biologics License Application for sickle cell disease (SCD) gene therapy lovo-cel.